Ulisse Biomed HPV solutions are confirmed among global molecular testing best practices.

Ulisse Biomed HPV solutions are confirmed among global molecular testing best practices.

Ulisse Biomed HPV solutions are confirmed among global molecular testing best practices.

A recent article analyzed the context of commercially available HPV molecular tests. In the last three years, new tests and new tests variants have been released.

"However, still, only 21% of all HPV tests currently available on the market [...] had data to support the claim that the tests’ clinical and/or analytical performance characteristics are in line with requirements agreed in the HPV community. [...] In conclusion, only a relatively small pool of HPV tests currently on the market fulfil the operational/performance characteristics required to meet the global cervical cancer screening challenge".

Ulisse Biomed HPV molecular tests meet all quality, operational and performance requirements, being also included in the last report of validated test from the Italian Group For Cervical Cancer Screening (GISCi).

"At Ulisse Biomed, thanks also to the integration with Hyris and its proprietary solution, we are working to provide quality, effective and efficient solutions for lab operators and clinicians" explains Gabriele Salaris, Head of Marketing and Sales at Ulisse Biomed. "We started from HPV genotyping solutions, we continued with Sexually Transmitted Diseases and are now focusing on new syndromic panels that will be released soon", concludes.